Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer

Author(s): Jan J. Melenhorst, Simon F. Lacey, Felipe Bedoya

Journal Name: Current Drug Targets

Volume 18 , Issue 3 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

The chimeric antigen receptor (CAR) technology started out as a tool to understand lymphocyte biology but rapidly developed into a T cell therapeutic agent for the treatment of cancers. Here, we describe the technological advances in the field of CARs and highlight critical components of its success. Additionally, we describe how various laboratories have worked toward developing new, safer, and more potent CARs for cancer.

Keywords: Cell therapy, chimeric antigen receptor (CAR), gene therapy, synthetic biology.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 3
Year: 2017
Published on: 23 January, 2017
Page: [332 - 340]
Pages: 9
DOI: 10.2174/1389450116666150825120427
Price: $65

Article Metrics

PDF: 42
HTML: 1
EPUB: 2
PRC: 1